Who We Are
The people you want to work with.
Engagement
We don’t just get things done, we have a good time along the way. Pharmica consultants are incredibly … normal. We relate. We’ll leave you with great results and great stories too.
Expertise
Since 2005, our consultants have been on the front lines of every aspect of the biopharma industry’s changes. We temper our acumen with your company’s unique particulars, so you get the best solution.
Execution
We bring clarity and results to your problems – not more meetings and slideware. Pharmica consultants have the focus and flexibility to bring great ideas from the back of the napkin to the forefront of your organization.
Services
How we help you Get Better.
-
Pharmacovigilance
Implementing global systems and processes so you can Get Better patient safety. -
Technology Solutions & Implementation
Putting new tools in place so you can Get Better results. -
Data Visualization & Analytics
Harvesting and simplifying data so you can Get Better insights. -
Process Improvement
Streamlining and coordinating work so you can Get Better reliability. -
Organizational Change
Cultivating understanding in your group so you can Get Better outcomes. -
Compliance & Quality
Designing conformity for standards so you can Get Better consistency. -
Vendor Selection & Management
Understanding how best to collaborate so you Get Better partnerships. -
Content Strategy
Streamlining and organizing your information so you Get Better knowledge. -
Operations
Providing resources when they're needed most so you can Get Better work. -
Resource & Portfolio Management
Understanding needs and facilitating plans so you can Get Better execution. -
Patient Engagement
Listening and integrating patient voice so you can Get Better engagement.
About Us
We are not “those” consultants.
For over ten years, Pharmica Consulting has been focused on helping the BioPharma industry maximize the contribution to their companies’ bottom lines. We combine extensive R&D and marketing experience with business management expertise to help make sound business decisions. We help your organization get better so that your scientists can do what they do best. Change in BioPharma has become increasingly unrelenting; and our industry’s landscape is more fluid than ever. Pharmica consultants are singled out for their industry understanding and focus on execution – but we’re most proud of our reputation as relatable, likeable people who make getting work done easy. Our vast experience and tailored consulting methodologies are the driving forces behind helping companies make distinctive and lasting improvements. Pharmica consultants come from Pharma R&D, marketing, and corporate backgrounds – not new grads or other industry transplants – so we can start improving your business on day one.
Repeat Client Rate
Consultants with Pharma Experience
Consultant Professional Certification
Our Team
Meet our team of personable, friendly consultants – real problem solvers with the industry expertise to get things done.
Matt Kiernan
Eric Lake
Greg Cohee
Nicholas Lagrotta
John Bennett
Mark Eckert
Billy Dee
Kristen Paterson
Matthew Baran
Andy Grubb
Madhu Nalubandu
Earon Sotto
Sravani Uppalapati
Helen Weiner
Amanda Adamek
Adam Kammler
Sean Meighan
Elliot Porter
Jared Shockcor
Jack Ozment
Amanda Onuskanich
Natalie Brody
Jennie Keough
Becky McGoldrick
Wendy Harris
Events
BLOGS
Ideas and insights from Pharmica's Consultants.
Will Remote Clinical Trials Become the New Norm?
By some counts, prescription drug costs account for 20 % of all healthcare costs. The cost of getting a drug to market reaching well over a billion dollars and there is a growing scrutiny of money-conscious consumers. It is not hard to see why pharma companies are searching to find ways to reduce costs. Clinical[…]
Are We Moving Beyond Patient Centricity to Collaborative Health?
It has only been a couple of decades since the concept of patient-centered care or patient centricity entered our collective consciousness. However, much has changed and continues to change rapidly in the healthcare industry. Technological, economic, and social advancements are moving at break-neck speed and propelling the industry into ever evolving directions. We could already[…]
Too Much Data – Too Little Information
The more data we gather, the more it takes to make sense of it. Gathering data is only the beginning – once you have it, you must make it meaningful. What trends can you identify? How can the information help? Data is only worth collecting if it can be used to help get questions answered and[…]
Survey Shows Barriers to Clinical Trial Recruitment
We have long known the challenges of clinical trial recruitment. So it’s not a surprise that a new survey conducted by SubjectWell shows that a general lack of awareness is a major hurdle in clinical trial recruitment. The Pharma industry spends more than $2 billion per year on clinical trial recruitment. However, these dollars don’t[…]
Analog & Digital Approaches to Better Patient Engagement
Patients and regulatory authorities are asking for more patient/sponsor communication over the drug development cycle. At the same time, many sponsors seek to better understand the value of different investments to meet this demand. They are converting patient insights into journey maps and case studies that are producing a variety of new technologies and services[…]
Can Drug Development be AGILE? – Part II
Agile Methodology is not new – except in the realm of clinical drug development. As you will see, there are ways to use this old IT technique to enhance your drug development team’s chances of hitting their goals. Agile methods were developed to overcome weaknesses in a conventional engineering process. Agile development can provide important benefits.[…]
Can Drug Development be AGILE?
Drug development is no easy task. With the enormous resources the process consumes, and the risk inherent in every drug program, it’s no wonder biopharma companies are always striving for an edge when it comes to managing their portfolios. Today’s big problems in managing these programs are nothing new: Costs – The cost to develop[…]
New Trends in Clinical Trials Focus on Patient Engagement
A recent BioPharma Dive article on the five trends changing clinical trials – patient centricity, tapping into technology (e.g. mobile devices), wearables (e.g. remote blood glucose monitors), flexibility (in trial design), and automated site supplies – has an interesting trend in the article itself. So, what’s the overarching trend? Four out of the five trends[…]
Patient Engagement Solutions – Portal Use is on the Rise
As a patient engagement solution, healthcare portals are nothing new. But for healthcare providers, getting patients to use their portals hasn’t been easy. Now it looks like portal use is on the rise and with that a hope of greater patient engagement. A recent CDW survey of 200 patients and providers has shown a jump[…]
Pharmacovigilance Webinar: Avoid CAPAs and Enhance Health Authority Inspection Readiness
Anxious that your upcoming Health Authority Inspection will bring more CAPAs? Your organization spends a considerable amount of effort and resources on processing pharmacovigilance cases — but you’re still not sure your upcoming inspection will leave you without an additional CAPA headache. Ever wonder what it would be like to go into an inspection confident[…]
Health Care Leaders Encourage Trump Administration to Keep Patient-Centered Health Care a Priority
Within five days of the inauguration, the Health Care Transformation Task Force (HTTF) sent a letter to President Trump and Vice President Pence with an urgent message. That message . . . continue to keep the value-based, patient-centered health care model a priority. Put the needs of patients first! The task force includes leaders throughout the industry.[…]
Patient Engagement – Ensuring Diversity in Clinical Trials
No one would disagree that diversity in clinical trials is critical. Diversity ensures that novel drugs will be effective and safe for all patients. But, a new FDA report shows that clinical trials may not reflect real-world demographics. And these trials may not be diverse enough to ensure patient safety. For instance, the latest report shows only 48% of drug[…]